Creative Biolabs Enhances Gene Therapy Research with Expanded Liposomal Drug Delivery Services
TL;DR
Creative Biolabs' liposomal drug delivery technology offers a competitive edge by enhancing drug bioavailability and reducing toxicity, crucial for advancing in gene therapy and oncology research.
Creative Biolabs customizes liposome formulations for nucleic acid and prodrug loading, optimizing stability and release kinetics through scalable manufacturing processes from bench to production.
By improving targeted drug delivery, Creative Biolabs contributes to safer and more effective treatments, paving the way for breakthroughs in cancer therapy and genetic diseases.
Discover how Creative Biolabs' LipoDrive™ platform revolutionizes drug delivery with liposomes that respond to pH, enzymes, or heat for precise cancer therapy.
Found this article helpful?
Share it with your network and spread the knowledge!
Creative Biolabs has announced the expansion of its liposomal drug delivery services, a move set to accelerate discoveries in gene therapy, oncology, and molecular medicine. This development underscores the company's commitment to providing customized liposome formulations tailored to the specific needs of global research institutes and pharmaceutical industries. Liposomal drug delivery, known for its ability to ensure targeted delivery, enhance bioavailability, and reduce toxicity, represents a significant advancement in modern therapeutics.
According to a spokesperson for Creative Biolabs, the company aims to equip scientists with the most advanced and versatile liposomal platforms available. These platforms are designed to address critical challenges in the field, such as stabilizing labile nucleic acids and modulating prodrug release in tumor microenvironments. The company's services include liposomal formulation development, nucleic acid encapsulation, and prodrug delivery solutions, all of which are customizable to meet the unique requirements of each project.
One of the key offerings is the LipoDrive™ platform, which supports advanced lipid synthesis, functionalization, and characterization. This enables researchers to design liposomes with precise pharmacokinetics and biodistribution profiles. Creative Biolabs' services are available to research institutions, biotech organizations, and pharmaceutical corporations across North America, Europe, and globally. However, it's important to note that these services are intended for research purposes only and not for clinical use.
For those interested in learning more about Creative Biolabs' liposomal drug delivery services or in placing an order for a customized development plan, further information can be found at https://www.creative-biolabs.com/lipid-based-delivery/. This expansion by Creative Biolabs is poised to make a significant impact on the field of gene therapy and beyond, offering researchers the tools they need to push the boundaries of biomedical research.
Curated from 24-7 Press Release
